Royalty Pharma plc
RPRX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.47 | 0.73 | -0.22 | 0.01 |
| FCF Yield | 2.74% | 4.50% | 6.53% | 5.58% |
| EV / EBITDA | 144.04 | 39.66 | 45.14 | 22.08 |
| Quality | ||||
| ROIC | 1.16% | 3.07% | 2.01% | 4.11% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -1.38 | 14.15 | 1.38 | 2.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.37% | -0.80% | -1.36% | 0.39% |
| Free Cash Flow Growth | -28.37% | -19.72% | 5.53% | 6.90% |
| Safety | ||||
| Net Debt / EBITDA | 46.27 | 13.09 | 16.70 | 7.63 |
| Interest Coverage | 3.06 | 8.19 | 5.50 | 11.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 4.31 | 3.77 | 4.09 | 3.97 |